Cargando…

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients

Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The present study was performed to identify the predictive factors of TKI-induced HT and to determine the classes of antihypertensive agents (AHTA) that d...

Descripción completa

Detalles Bibliográficos
Autores principales:	IZUMI, KOUJI, ITAI, SHINGO, TAKAHASHI, YOSHIKO, MAOLAKE, AERKEN, NAMIKI, MIKIO
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063571/ https://www.ncbi.nlm.nih.gov/pubmed/24959266 http://dx.doi.org/10.3892/ol.2014.2060

Ejemplares similares

Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis
por: Maolake, Aerken, et al.
Publicado: (2016)

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2015)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Tumor necrosis factor‐α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation
por: Maolake, Aerken, et al.
Publicado: (2018)

CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
por: Natsagdorj, Ariunbold, et al.
Publicado: (2018)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019)

Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment
por: Kaneko, Shun, et al.
Publicado: (2022)

C‐C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment
por: Urata, Satoko, et al.
Publicado: (2018)

Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report
por: Yaegashi, Hiroshi, et al.
Publicado: (2015)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Clinical-radiomic model in advanced kidney cancer predicts response to tyrosine kinase inhibitors
por: Negreros-Osuna, Adrián A., et al.
Publicado: (2022)

Inflammatory Myofibroblastic Tumor of the Urinary Bladder with Benign Pelvic Lymph Node Enlargement: A Case Report
por: Machioka, Kazuaki, et al.
Publicado: (2014)

Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor
por: Harada, Mirii, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
por: Pitsiou, Georgia, et al.
Publicado: (2014)

Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors
por: Kadowaki, Hiroshi, et al.
Publicado: (2021)

A Small Molecule Inhibitor of Bruton’s Tyrosine Kinase Involved in B-Cell Signaling
por: Ratzon, Einav, et al.
Publicado: (2017)

Receptor Tyrosine Kinases in Kidney Development
por: Song, Renfang, et al.
Publicado: (2011)

The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease
por: Jamadar, Abeda, et al.
Publicado: (2021)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2019)

Receptor tyrosine kinases modulate distinct transcriptional programs by differential usage of intracellular pathways
por: Vasudevan, Harish N, et al.
Publicado: (2015)

Tyrosine Kinase Signaling in Kidney Glomerular Podocytes
por: Hattori, Seisuke, et al.
Publicado: (2011)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
por: Hennigs, Jan K, et al.
Publicado: (2011)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
por: Tanaka, Atsushi, et al.
Publicado: (2019)

The impact of antihypertensives on kidney disease
por: Marquez, Diego F, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
por: Gomez-Puerta, Jose A., et al.
Publicado: (2013)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cijbnga2ialatesottu26ue8u3